Emtricitabine and tenofovir disoproxil fumarate
- Generic Name
- Emtricitabine and tenofovir disoproxil fumarate
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
适用于与其他抗逆转录病毒药物联用，治疗成人和12岁（含）以上儿童的 HIV-1感染。
- Associated Conditions
- -
- Associated Therapies
- -
PrEP With TDF/FTC to Prevent HIV-1 Acquisition in Young MSM and Transgender Women of Color
Completed
- Conditions
- First Posted Date
- 2015-02-20
- Last Posted Date
- 2016-10-11
- Lead Sponsor
- Philadelphia Fight
- Target Recruit Count
- 50
- Registration Number
- NCT02367807
- Locations
- 🇺🇸
Philadelphia FIGHT, Philadelphia, Pennsylvania, United States
Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-01-27
- Last Posted Date
- 2016-11-29
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 20
- Registration Number
- NCT01285050
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects (Study P04875)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2015-02-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 218
- Registration Number
- NCT00551018
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath